{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:34:30Z","timestamp":1793759670980,"version":"4.6.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"8114","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2026,5,14]]},"DOI":"10.1038\/s41586-026-10405-x","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T15:02:27Z","timestamp":1776265347000},"page":"558-566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Prospective evaluation of genomics-guided off-label treatment"],"prefix":"10.1038","volume":"653","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5882-4980","authenticated-orcid":false,"given":"K.","family":"Verkerk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. C.","family":"Spiekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. F.","family":"Haj Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. A. J.","family":"Verbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3822-7326","authenticated-orcid":false,"given":"H.","family":"Timmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8799-4821","authenticated-orcid":false,"given":"M. A.","family":"van Maren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. J.","family":"Zeverijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. S.","family":"Geurts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4910-4535","authenticated-orcid":false,"given":"V.","family":"van der Noort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Roepman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M. L.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. W. J.","family":"de Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-8636","authenticated-orcid":false,"given":"H.","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. M. W.","family":"Verheul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8249-9586","authenticated-orcid":false,"given":"E. E.","family":"Voest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The DRUP Trial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. H.","family":"Nienhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"van Dodewaard-de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Labots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J. A.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"van Herpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hoeben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. V.","family":"Beerepoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. D.","family":"Kerver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. M.","family":"Westgeest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. D.","family":"Bins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. P.","family":"Hamberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Boon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Vreugdenhil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. J.","family":"de Klerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"van Voorthuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vulink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"van den Berkmortel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"van Rooijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Houtsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. L. T.","family":"Imholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. P.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A. J.","family":"Douma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"de Mol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hovenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. P.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. W. B.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Los","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Boudewijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. N.","family":"Klein Hesselink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Siemerink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. C. S.","family":"Tromp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Davidis-van Schoonhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Jeurissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"10405_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-019-1600-x","volume":"574","author":"DL van der Velden","year":"2019","unstructured":"van der Velden, D. L. et al. The Drug Rediscovery Protocol facilitates the expanded use of existing anticancer drugs. Nature 574, 127\u2013131 (2019).","journal-title":"Nature"},{"key":"10405_CR2","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1158\/1078-0432.CCR-24-0480","volume":"30","author":"LJ Zeverijn","year":"2024","unstructured":"Zeverijn, L. J. et al. The innate immune landscape of dMMR\/MSI cancers predicts outcome of nivolumab treatment: results from the Drug Rediscovery Protocol. Clin. Cancer Res. 30, 4339\u20134351 (2024).","journal-title":"Clin. Cancer Res."},{"key":"10405_CR3","first-page":"731","volume":"14","author":"D Gentile","year":"2018","unstructured":"Gentile, D., Markham, M. J. & Eaton, T. Patients with cancer and social media: harness benefits, avoid drawbacks. J. Clin. Oncol. 14, 731\u2013736 (2018).","journal-title":"J. Clin. Oncol."},{"key":"10405_CR4","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/S1470-2045(17)30445-X","volume":"18","author":"G Gatta","year":"2017","unstructured":"Gatta, G. et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet\u2013a population-based study. Lancet Oncol. 18, 1022\u20131039 (2017).","journal-title":"Lancet Oncol."},{"key":"10405_CR5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41586-019-1689-y","volume":"575","author":"P Priestley","year":"2019","unstructured":"Priestley, P. et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature 575, 210\u2013216 (2019).","journal-title":"Nature"},{"key":"10405_CR6","doi-asserted-by":"publisher","first-page":"17112","DOI":"10.1002\/cam4.6360","volume":"12","author":"S Fontanals","year":"2023","unstructured":"Fontanals, S. et al. Real-world treatment outcomes of medicines used in special situations (off-label and compassionate use) in oncology and hematology: A retrospective study from a comprehensive cancer institution. Cancer Med. 12, 17112\u201317125 (2023).","journal-title":"Cancer Med."},{"key":"10405_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101444","volume":"5","author":"R Liu","year":"2024","unstructured":"Liu, R. et al. Systematic analysis of off-label and off-guideline cancer therapy usage in a real-world cohort of 165,912 US patients. Cell Rep. Med. 5, 101444 (2024).","journal-title":"Cell Rep. Med."},{"key":"10405_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","volume":"20","author":"CH Wong","year":"2019","unstructured":"Wong, C. H., Siah, K. W. & Lo, A. W. Estimation of clinical trial success rates and related parameters. Biostatistics 20, 273\u2013286 (2019).","journal-title":"Biostatistics"},{"key":"10405_CR9","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri, G. D. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472\u2013480 (2002).","journal-title":"N. Engl. J. Med."},{"key":"10405_CR10","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783\u2013792 (2001).","journal-title":"N. Engl. J. Med."},{"key":"10405_CR11","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687\u2013697 (2010).","journal-title":"Lancet"},{"key":"10405_CR12","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty, K. T. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694\u20131703 (2012).","journal-title":"N. Engl. J. Med."},{"key":"10405_CR13","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","volume":"33","author":"S Kopetz","year":"2015","unstructured":"Kopetz, S. et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J. Clin. Oncol. 33, 4032\u20134038 (2015).","journal-title":"J. Clin. Oncol."},{"key":"10405_CR14","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","volume":"16","author":"C Le Tourneau","year":"2015","unstructured":"Le Tourneau, C. et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 16, 1324\u20131334 (2015).","journal-title":"Lancet Oncol."},{"key":"10405_CR15","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.3389\/fphar.2019.01664","volume":"10","author":"C Verbaanderd","year":"2019","unstructured":"Verbaanderd, C., Rooman, I., Meheus, L. & Huys, I. On-label or off-label? Overcoming regulatory and financial barriers to bring repurposed medicines to cancer patients. Front. Pharmacol. 10, 1664 (2019).","journal-title":"Front. Pharmacol."},{"key":"10405_CR16","doi-asserted-by":"publisher","first-page":"e210380","DOI":"10.1001\/jamanetworkopen.2021.0380","volume":"4","author":"AK Herbrand","year":"2021","unstructured":"Herbrand, A. K. et al. Association of supporting trial evidence and reimbursement for off-label use of cancer drugs. JAMA Netw. Open 4, e210380 (2021).","journal-title":"JAMA Netw. Open"},{"key":"10405_CR17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/annonc\/mdz119","volume":"30","author":"SB van Waalwijk van Doorn-Khosrovani","year":"2019","unstructured":"van Waalwijk van Doorn-Khosrovani, S. B. et al. Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients. Ann. Oncol. 30, 663\u2013665 (2019).","journal-title":"Ann. Oncol."},{"key":"10405_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000666","volume":"5","author":"PG Casali","year":"2020","unstructured":"Casali, P. G. & Trama, A. Rationale of the rare cancer list: a consensus paper from the Joint Action on Rare Cancers (JARC) of the European Union (EU). ESMO Open 5, e000666 (2020).","journal-title":"ESMO Open"},{"key":"10405_CR19","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/ijc.34649","volume":"153","author":"LJ Zeverijn","year":"2023","unstructured":"Zeverijn, L. J. et al. Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4\/6 pathway alterations in the Dutch DRUP and Australian MoST trials. Int. J. Cancer 153, 1413\u20131422 (2023).","journal-title":"Int. J. Cancer"},{"key":"10405_CR20","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1158\/1078-0432.CCR-24-0480","volume":"30","author":"LJ Zeverijn","year":"2024","unstructured":"Zeverijn, L. J. et al. The innate immune landscape of dMMR\/MSI cancers predicts the outcome of nivolumab treatment: results from the drug rediscovery protocol. Clin. Cancer Res. 30, 4339\u20134351 (2024).","journal-title":"Clin. Cancer Res."},{"key":"10405_CR21","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2340\/1651-226X.2024.34791","volume":"63","author":"K Task\u00e9n","year":"2024","unstructured":"Task\u00e9n, K. et al. PCM4EU and PRIME-ROSE: collaboration for implementation of precision cancer medicine in Europe. Acta Oncol. 63, 385\u2013391 (2024).","journal-title":"Acta Oncol."},{"key":"10405_CR22","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41591-019-0424-4","volume":"25","author":"J Rodon","year":"2019","unstructured":"Rodon, J. et al. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat. Med. 25, 751\u2013758 (2019).","journal-title":"Nat. Med."},{"key":"10405_CR23","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","volume":"25","author":"JK Sicklick","year":"2019","unstructured":"Sicklick, J. K. et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat. Med. 25, 744\u2013750 (2019).","journal-title":"Nat. Med."},{"key":"10405_CR24","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1158\/1078-0432.CCR-21-3752","volume":"28","author":"LR Hoes","year":"2022","unstructured":"Hoes, L. R. et al. Patients with rare cancers in the Drug Rediscovery Protocol (DRUP) benefit from genomics-guided treatment. Clin. Cancer Res. 28, 1402\u20131411 (2022).","journal-title":"Clin. Cancer Res."},{"key":"10405_CR25","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/s41591-023-02379-4","volume":"29","author":"PJ O\u2019Dwyer","year":"2023","unstructured":"O\u2019Dwyer, P. J. et al. The NCI-MATCH trial: lessons for precision oncology. Nat. Med. 29, 1349\u20131357 (2023).","journal-title":"Nat. Med."},{"key":"10405_CR26","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","volume":"36","author":"JD Hainsworth","year":"2018","unstructured":"Hainsworth, J. D. et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results From MyPathway, an open-label, phase IIa multiple basket study. J. Clin. Oncol. 36, 536\u2013542 (2018).","journal-title":"J. Clin. Oncol."},{"key":"10405_CR27","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ejca.2022.10.027","volume":"178","author":"A Haslam","year":"2023","unstructured":"Haslam, A., Olivier, T., Tuia, J. & Prasad, V. A systematic review of basket and umbrella trials in oncology: the importance of tissue of origin and molecular target. Eur. J. Cancer 178, 227\u2013233 (2023).","journal-title":"Eur. J. Cancer"},{"key":"10405_CR28","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1080\/0284186X.2022.2098053","volume":"61","author":"AH Ree","year":"2022","unstructured":"Ree, A. H. et al. Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer - the MetAction precision medicine study. Acta Oncol. 61, 955\u2013962 (2022).","journal-title":"Acta Oncol."},{"key":"10405_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.754390","volume":"12","author":"N Gordon","year":"2021","unstructured":"Gordon, N., Goldstein, D. A., Tadmor, B., Stemmer, S. M. & Greenberg, D. Factors associated with off-label oncology prescriptions: the role of cost and financing in a universal healthcare system. Front. Pharmacol. 12, 754390 (2021).","journal-title":"Front. Pharmacol."},{"key":"10405_CR30","first-page":"1","volume":"2","author":"PK Mangat","year":"2018","unstructured":"Mangat, P. K. et al. Rationale and design of the Targeted Agent and Profiling Utilization Registry study. J. Precis. Oncol. 2, 1\u201314 (2018).","journal-title":"J. Precis. Oncol."},{"key":"10405_CR31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS12127","volume":"36","author":"T Skamene","year":"2018","unstructured":"Skamene, T. et al. Canadian profiling and targeted agent utilization trial (CAPTUR\/PM.1): a phase II basket precision medicine trial. J. Clin. Oncol. 36, TPS12127 (2018).","journal-title":"J. Clin. Oncol."},{"key":"10405_CR32","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","volume":"29","author":"J Mateo","year":"2018","unstructured":"Mateo, J. et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann. Oncol. 29, 1895\u20131902 (2018).","journal-title":"Ann. Oncol."},{"key":"10405_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00011","volume":"1","author":"D Chakravarty","year":"2017","unstructured":"Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. 1, 1\u201316 (2017).","journal-title":"JCO Precis. Oncol."},{"key":"10405_CR34","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","volume":"35","author":"MF Mosele","year":"2024","unstructured":"Mosele, M. F. et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann. Oncol. 35, 588\u2013606 (2024).","journal-title":"Ann. Oncol."},{"key":"10405_CR35","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.annonc.2025.04.004","volume":"36","author":"L Belcaid","year":"2025","unstructured":"Belcaid, L. et al. Copenhagen Prospective Personalized Oncology (CoPPO)\u2014impact of comprehensive genomic profiling in more than 2000 patients in a phase I setting. Ann. Oncol. 36, 1078\u20131087 (2025).","journal-title":"Ann. Oncol."},{"key":"10405_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18613-3","volume":"11","author":"S Kato","year":"2020","unstructured":"Kato, S. et al. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat. Commun. 11, 4965 (2020).","journal-title":"Nat. Commun."},{"key":"10405_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57941-0","volume":"16","author":"GW Sledge","year":"2025","unstructured":"Sledge, G. W. et al. Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals. Nat. Commun. 16, 2646 (2025).","journal-title":"Nat. Commun."},{"key":"10405_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114262","volume":"209","author":"NSH Xander","year":"2024","unstructured":"Xander, N. S. H. et al. Using non-randomized trials to assess the clinical benefit of systemic anti-cancer treatments: viable or not? Eur. J. Cancer 209, 114262 (2024).","journal-title":"Eur. J. Cancer"},{"key":"10405_CR39","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","volume":"26","author":"NI Cherny","year":"2015","unstructured":"Cherny, N. I. et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann. Oncol. 26, 1547\u20131573 (2015).","journal-title":"Ann. Oncol."},{"key":"10405_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2024.100492","volume":"41","author":"J Smids","year":"2024","unstructured":"Smids, J., Bomhof, C., Ijzerman, M. & Bunnik, E. Whole genome sequencing as a ticket to cancer treatment in the Netherlands: are inequalities in access to molecular diagnostics unfair? J. Cancer Pol. 41, 100492 (2024).","journal-title":"J. Cancer Pol."},{"key":"10405_CR41","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"10405_CR42","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/sim.1600","volume":"23","author":"SH Jung","year":"2004","unstructured":"Jung, S. H., Lee, T., Kim, K. & George, S. L. Admissible two-stage designs for phase II cancer clinical trials. Stat. Med. 23, 561\u2013569 (2004).","journal-title":"Stat. Med."},{"key":"10405_CR43","doi-asserted-by":"crossref","unstructured":"van der Wijngaart, H. et al. Patients with biallelic BRCAl\/2 inactivation respond to olaparib treatment across histologic tumor types. Clin. Cancer Res. 27, 6106\u20136114 (2021).","DOI":"10.1158\/1078-0432.CCR-21-1104"},{"key":"10405_CR44","doi-asserted-by":"crossref","unstructured":"van Berge Henegouwen, J. M. et al. Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer. Eur. J. Cancer 171, 114\u2013123 (2022).","DOI":"10.1016\/j.ejca.2022.05.009"},{"key":"10405_CR45","doi-asserted-by":"crossref","unstructured":"Geurts, B. S. et al. Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours. BMC Cancer 23, 205 (2023).","DOI":"10.1186\/s12885-023-10663-2"},{"key":"10405_CR46","doi-asserted-by":"crossref","unstructured":"Spiekman, I. A. C. et al. Efficacy and safety of panitumumab in patients with RAF\/RAS-wild-type glioblastoma: results from the Drug Rediscovery Protocol. Oncologist 29, 431\u2013440 (2024).","DOI":"10.1093\/oncolo\/oyad320"},{"key":"10405_CR47","doi-asserted-by":"crossref","unstructured":"Spiekman, I. A. C. et al. Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: results from the Drug Rediscovery Protocol (DRUP). Eur. J. Cancer 202, 113988 (2024).","DOI":"10.1016\/j.ejca.2024.113988"},{"key":"10405_CR48","doi-asserted-by":"crossref","unstructured":"Geurts, B. S. et al. Efficacy of pembrolizumab and biomarker analysis in patients with WGS-based intermediate to high tumor mutational load: results from the Drug Rediscovery Protocol. Clin. Cancer Res. 30, 3735\u20133746 (2024).","DOI":"10.1158\/1078-0432.CCR-24-0011"},{"key":"10405_CR49","doi-asserted-by":"crossref","unstructured":"Verkerk, K. et al. Safety, efficacy, and biomarker analysis of crizotinib in MET-mutated non-small cell lung cancer\u2014results from the Drug Rediscovery Protocol. Clin. Cancer Res. 30, 5323\u20135332 (2024).","DOI":"10.1158\/1078-0432.CCR-24-1925"},{"key":"10405_CR50","doi-asserted-by":"publisher","unstructured":"Spiekman, I. A. C. et al. Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: results from the Drug Rediscovery Protocol. Int. J. Cancer https:\/\/doi.org\/10.1002\/ijc.70191 (2025).","DOI":"10.1002\/ijc.70191"},{"key":"10405_CR51","doi-asserted-by":"publisher","unstructured":"Verkerk, K. et al. Checkpoint blockade combinations in high tumor mutational burden\/load tumors: insights from the atezolizumab + bevacizumab and nivolumab + lpilimumab cohorts in DRUP. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-25-2260 (2025).","DOI":"10.1158\/1078-0432.Ccr-25-2260"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10405-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10405-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10405-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:02:46Z","timestamp":1778745766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10405-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":51,"journal-issue":{"issue":"8114","published-print":{"date-parts":[[2026,5,14]]}},"alternative-id":["10405"],"URL":"https:\/\/doi.org\/10.1038\/s41586-026-10405-x","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.G. is a board member of the Center for Personalized Cancer Treatment, coordinator of PCM4EU, co-coordinator of PRIME-ROSE and a member of the advisory committee of health care reimbursement (ACP) of Zorginstituut Nederland. E.E.V. is founder and current member of the supervisory board of the Hartwig Medical Foundation, independent non-executive director and shareholder of Sanofi, co-founder and shareholder of Mosaic Therapeutics and a board member and founder of the Center for Personalized Cancer Treatment. E.E.V. has received clinical study grants from Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Clovis, Eisai, Eli Lilly, GSK, Ipsen, Johnson & Johnson, MSD, Novartis, Pfizer, Roche and Sanofi, all paid to the Netherlands Cancer Institute. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}